Ailicon

Ailicon is an artificial intelligence-driven biotechnology company focused on the discovery and design of innovative therapeutic antibodies and proteins. Headquartered in Suzhou, China, the company leverages a proprietary AI platform that integrates deep learning, computational structural biology, and high-throughput experimental data to accelerate drug development. Ailicon's technology aims to optimize the affinity, specificity, and developability of biologics, significantly reducing the time and cost of traditional discovery cycles. The company's internal pipeline primarily targets unmet needs in oncology and immunology. By combining computational dry-lab expertise with wet-lab validation, Ailicon strives to deliver high-quality clinical candidates for complex disease targets.